Evidence map›Paper›PMID 33995361›Full record

ArticleFrontiers in immunology2021

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.

Gergely Tibor Kozma, Tamás Mészáros, Tamás Bakos, Mark Hennies, Dániel Bencze, Barbara Uzonyi, Balázs Győrffy, Edward Cedrone, Marina A Dobrovolskaia, Mihály Józsi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The human factor H protein family - an update.Frontiers in immunology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Gergely Tibor KozmaNanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Tamás MészárosNanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Tamás BakosNanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Mark HenniesTECOdevelopment GmbH, Rheinbach, Germany.
Dániel BenczeMTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary.
Barbara UzonyiMTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary.
Balázs GyőrffySecond Department of Bioinformatics and Pediatrics, Semmelweis University, Budapest, Hungary.
Edward CedroneNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Marina A DobrovolskaiaNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Mihály JózsiMTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary.
János SzebeniNanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUEötvös Loránd University · HUFrederick National Laboratory for Cancer Research · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Cytokine storm (CS), an excessive release of proinflammatory cytokines upon overactivation of the innate immune system, came recently to the focus of interest because of its role in the life-threatening consequences of certain immune therapies and viral diseases, including CAR-T cell therapy and Covid-19. Because complement activation with subsequent anaphylatoxin release is in the core of innate immune stimulation, studying the relationship between complement activation and cytokine release in an

Indexed as

Complement ActivationModels, ImmunologicalComplement Factor HCOVID-19Cytokine Release SyndromeHumansInterleukin-10Interleukin-6Leukocytes, MononuclearSARS-CoV-2CFH protein, humanComplement Factor HIL10 protein, humanIL6 protein, humanInterleukin-10Interleukin-6anaphylatoxinscomplement activation/inhibitionCOVID-19cytokine release syndromefactor Himmune stimulationwhole blood assayzymosan

Identifiers

PMID33995361
PMCPMC8113956
OpenAlexW3159883037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.